Development of a Palladium-Catalyzed α-Arylation of Cyclopropyl Nitriles
作者:Jamie M. McCabe Dunn、Jeffrey T. Kuethe、Robert K. Orr、Matthew Tudge、Louis-Charles Campeau
DOI:10.1021/ol5030426
日期:2014.12.19
access to a range of cyclopropyl derivatives. Herein, we describe the development of a palladium-catalyzed α-arylation of cyclopropyl, cyclobutyl, and cyclopentyl nitriles that affords these functional groups in one step from a variety of aryl bromides in good to excellent yields. Furthermore, we demonstrate the transformation of aryl cyclopropyl nitriles into aryl trifluoromethyl cyclopropanes.
Rhodium‐Catalyzed Enantioselective Silylation of Cyclopropyl C−H Bonds
作者:Taegyo Lee、John F. Hartwig
DOI:10.1002/anie.201603153
日期:2016.7.18
Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C−Hbonds in high yields and with high enantiomeric excesses in the presence of a rhodium catalyst derived from a rhodium precursor and the bisphosphine (S)‐DTBM‐SEGPHOS. The resulting enantioenriched oxasilolanes are suitable
氢硅烷基醚是通过环丙基甲醇与二乙基硅烷的脱氢硅烷化原位生成的,在源自铑前体和双膦的铑催化剂存在下,以高收率和高对映体过量进行环丙基CH键的不对称分子内硅烷化( S )-DTBM-SEGPHOS。所得的对映体富集的氧杂硅氧烷是 Tamao-Fleming 氧化形成环丙醇的合适底物,同时保留了 C−H 甲硅烷基化的ee值。初步的机制数据表明,C−H 裂解可能是转换限制和对映选择性决定步骤。
Tetrahydroisoquinoline derivatives
申请人:Bischoff Hilmar
公开号:US20050234096A1
公开(公告)日:2005-10-20
The invention relates to novel substituted tetrahydroisoquinoline derivatives, methods for the production thereof and the use thereof in medicaments, especially as potent PPAR-delta activating compounds for the prophylaxis and/or treatment of cardiovascular diseases, especially dislipidaemia, coronary heart disease and arteriosclerosis.
[DE] TETRAHYDROISOCHINOLIN-DERIVATE<br/>[EN] TETRAHYDROISOQUINOLINE DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDROISOQUINOLINE
申请人:BAYER HEALTHCARE AG
公开号:WO2003097607A1
公开(公告)日:2003-11-27
Die vorliegende Anmeldung betrifft neue substituierte Tetrahydroisochinolin-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln, insbesondere als potente PPAR-delta aktivierende Verbindungen zur Prophylaxe und/oder Behandlung kardiovaskulärer Erkrankungen, insbesondere von Dyslipidämien, koronaren Herzkrankheiten und Arteriosklerose.